Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New mRNA vaccine targets Epstein-Barr virus in first human trial

NCT ID NCT07557602

Vaccine Sponsor: Vaccine Company, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new mRNA vaccine called VXCO-102 against Epstein-Barr virus (EBV) in 45 healthy adults aged 18 to 25. The main goal is to check if the vaccine is safe and triggers an immune response. EBV is a common virus that can cause mononucleosis and is linked to some cancers, so a successful vaccine could have a big impact.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VXCO-102 (mRNA vaccine targeting Epstein-Barr virus)
What this could lead to
If successful, this could pave the way for a vaccine to prevent EBV infection, which is linked to mononucleosis and certain cancers.
What could go wrong
This is an early Phase 1 trial with only 45 participants, so it is primarily testing safety, not effectiveness. The vaccine may not produce a strong immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 25 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 25 years, inclusive * Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment Exclusion Criteria: * Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation * Likely or confirmed myocarditis or pericarditis * Prior receipt of an investigational EBV vaccine * Prior receipt of a licensed vaccine within 56 days prior to Day 1 * Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study. * For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study Note: Other inclusion and exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, 3004, Australia

  • Q-Pharm Pty Ltd/Nucleus Network Pty Ltd

    Herston, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.